Experts at Children's Hospital Boston and Dana-Farber Cancer Institute are internationally known for their laboratory and clinical research findings. In addition to offering the most Phase I clinical trials in New England, laboratory researchers at Children's and Dana-Farber examine every aspect of cancer from its scientific origin to molecular response to new drug combinations. As a result, findings from Children's and Dana-Farber have been responsible for dozens of advances in the treatment of pediatric cancer that have resulted in improved survival rates for nearly every variety of childhood cancer. Key accomplishments include the first successful remission of childhood leukemia by Sidney Farber, MD, in 1947 and introduction of multiple agent treatment (combination chemotherapy) for leukemia in 1972. With successful improvements, we have attained childhood leukemia cure rates of close to 80 percent.
Physicians from all over the world come to Boston to study pediatric hematology/oncology through the combined Dana-Farber Cancer Institute/Children's Hospital Boston's pediatric hematology-oncology fellowship program. This program has trained more leaders in the hematology and oncology field than any other. In fact, approximately 40 percent of the Hematology/Oncology Division Chiefs in the United States were trained through our program.